Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26186653 | 0.78 | MAPK10 (0.41) | KIF11MAPK10KDM4EALDH1A1 | |
| SCHEMBL30285904 | 0.76 | POLB (0.47) | MEN1KMT2AMAPTPHGDH | |
| SCHEMBL26186344 | 0.75 | KDR (0.44) | KIF11MAPK10KDM4E | |
| SCHEMBL25373160 | 0.74 | KMT2A (0.46) | MEN1KMT2AEPAS1MAPTMAPK1 | |
| SCHEMBL13428725 | 0.73 | STAT3 (0.53) | MEN1KMT2AMAPTALDH1A1PHGDH | |
| SCHEMBL4823456 | 0.73 | MPL (0.44) | MAPTTLR2TLR1KIF11KDM4E | |
| SCHEMBL10582677 | 0.72 | MAPT (0.57) | MEN1KMT2AEPAS1MAPTTLR2 | |
| SCHEMBL15169780 | 0.72 | AKR1B1 (0.42) | MEN1KMT2AEPAS1MAPTMAPK1 | |
| SCHEMBL29005456 | 0.72 | ROCK1 (0.47) | MEN1KMT2AMAPTMAPK10KDM4E | |
| SCHEMBL30285715 | 0.72 | ROCK1 (0.47) | MEN1KMT2AMAPTMAPK10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | MEN1 4807/4885KMT2A 4347/4885EPAS1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.